You are here
Incidence of capecitabine-related cardiotoxicity in different treatment schedules of metastatic colorectal cancer: A retrospective analysis of the CAIRO studies of the Dutch Colorectal Cancer Group
Johannes J.M. Kwakman , Lieke H.J. Simkens , Linda Mol , Wouter E.M. Kok , Miriam Koopman , Cornelis J.A. PuntEuropean Journal of Cancer, May 2017, Volume 76, Pages 93-99
Dr Ben SprangersRenal and cardiac toxicities of checkpoint inhibitors are rare. With monotherapy, the incidence of any-grade acute kidney injury was 1 to 2% and less than 1% for grades 3-4. It increased with the combination of nivolumab and ipilimumab to 5% for any-grade acute kidney injury …
Dr Marc CarrierDr Carrier reviewed the new evidence for acute and long-term treatment of cancer-associated thrombosis (CAT) and discussed the use of novel direct oral anticoagulant (DOAC) in this setting. With an approximate annual incidence of 1 per 200 and an annual death …
Reinbolt RE, Patel R, Pan X, Timmers CD, Pilarski R, Shapiro CL, Lustberg MB.Support Care Cancer. 2016 May;24(5):2173-80. doi: 10.1007/s00520-015-3008-y.
Prevention of cardiac dysfunction during adjuvant breast cancer therapy (PRADA): a 2 × 2 factorial, randomized, placebo-controlled, double-blind clinical trial of candesartan and metoprolol.
Gulati G, Heck SL, Ree AH, Hoffmann P, Schulz-Menger J, Fagerland MW, Gravdehaug B et al.Eur Heart J. 2016 Jun 1;37(21):1671-80. doi: 10.1093/eurheartj/ehw022. Epub 2016 Feb 21.
Presentation by Dr. Jean-Yves Pierga at the TAO Congress on 19/20 November 2015The first presentation of the session dedicated to “New therapies and supportive care in breast cancer” is by Dr. Jean-Yves...Category: Presentations
Re: The Incidence and Relative Risk of Cardiovascular Toxicity in Patients Treated with New Hormonal Agents for Castration-resistant Prostate Cancer
Jehonathan Pinthus, Christopher Morris
European Urology, Volume 69, Issue 1, January 2016, Pages 177-178
Presentation by Marine Sroussi at the TAO Congress on 19/20 November 2015The diagnosis of the 51-year-old male patient is lung adenocarcinoma without mutation in EGFR, ERBB2, KRAS or BRAF and without...Category: Presentations
Aapro M, Bernard-Marty C, Brain E, Batist G, Erdkamp F, Krzemieniecki K, Leonard R, Lluch A, Monfardini S, Ryberg M, Soubeyran P, Wedding UAnnals of Oncology 2011; 22(2): 257–67Category: Guidelines